AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $21.16 million. The enterprise value is $13.57 million.
| Market Cap | 21.16M |
| Enterprise Value | 13.57M |
Important Dates
The next estimated earnings date is Tuesday, August 13, 2024, before market open.
| Earnings Date | Aug 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 57.14 million shares outstanding. The number of shares has increased by 2.19% in one year.
| Shares Outstanding | 57.14M |
| Shares Change (YoY) | +2.19% |
| Shares Change (QoQ) | +1.16% |
| Owned by Insiders (%) | 7.97% |
| Owned by Institutions (%) | 7.17% |
| Float | 47.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 109.63 |
| Forward PS | n/a |
| PB Ratio | 4.38 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 70.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.15 |
| Quick Ratio | n/a |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -431.19 |
Financial Efficiency
Return on equity (ROE) is -183.60% and return on invested capital (ROIC) is -407.47%.
| Return on Equity (ROE) | -183.60% |
| Return on Assets (ROA) | -128.30% |
| Return on Capital (ROIC) | -407.47% |
| Revenue Per Employee | $6,893 |
| Profits Per Employee | -$1.11M |
| Employee Count | 28 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.59% in the last 52 weeks. The beta is -0.35, so AIM ImmunoTech's price volatility has been lower than the market average.
| Beta (5Y) | -0.35 |
| 52-Week Price Change | -46.59% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 0.43 |
| Relative Strength Index (RSI) | 46.09 |
| Average Volume (20 Days) | 169,664 |
Short Selling Information
The latest short interest is 461,705, so 0.81% of the outstanding shares have been sold short.
| Short Interest | 461,705 |
| Short Previous Month | 419,389 |
| Short % of Shares Out | 0.81% |
| Short % of Float | 0.98% |
| Short Ratio (days to cover) | 1.20 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $193,000 and -$31.12 million in losses. Loss per share was -$0.64.
| Revenue | 193,000 |
| Gross Profit | 143,000 |
| Operating Income | -33.32M |
| Pretax Income | -31.12M |
| Net Income | -31.12M |
| EBITDA | -30.58M |
| EBIT | -31.05M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $10.94 million in cash and $3.35 million in debt, giving a net cash position of $7.59 million or $0.13 per share.
| Cash & Cash Equivalents | 10.94M |
| Total Debt | 3.35M |
| Net Cash | 7.59M |
| Net Cash Per Share | $0.13 |
| Equity (Book Value) | 4.83M |
| Book Value Per Share | 0.08 |
| Working Capital | 1.43M |
Cash Flow
In the last 12 months, operating cash flow was -$22.40 million and capital expenditures -$32,000, giving a free cash flow of -$22.43 million.
| Operating Cash Flow | -22.40M |
| Capital Expenditures | -32,000 |
| Free Cash Flow | -22.43M |
| FCF Per Share | -$0.45 |
Margins
Gross margin is 74.09%, with operating and profit margins of -17,261.66% and -16,123.32%.
| Gross Margin | 74.09% |
| Operating Margin | -17,261.66% |
| Pretax Margin | -16,123.32% |
| Profit Margin | -16,123.32% |
| EBITDA Margin | -15,843.01% |
| EBIT Margin | -16,086.01% |
| FCF Margin | -11,623.83% |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.19% |
| Shareholder Yield | -2.19% |
| Earnings Yield | -147.08% |
| FCF Yield | -106.03% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | 202.96% |
| EPS Growth Forecast (5Y) | -21.24% |
Stock Splits
The last stock split was on June 11, 2019. It was a reverse split with a ratio of 1:44.
| Last Split Date | Jun 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:44 |
Scores
AIM ImmunoTech has an Altman Z-Score of -41.01 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -41.01 |
| Piotroski F-Score | 3 |